COMMUNIQUÉS West-GlobeNewswire

Biotricity to Host Fiscal 2026 Second Quarter Financial Results and Business Update Call on November 14th
07/11/2025
REDWOOD CITY, CA, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB:BTCY) ("Biotricity" or the "Company”), an innovative Technology-as-a-Service (TaaS) company committed to redefining the landscape of the [...]
Wave Life Sciences to Present at Upcoming Investor Conferences
07/11/2025
CAMBRIDGE, Mass., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, [...]
Ipsen présentera, lors de deux sessions « late-breaking » au congrès de l’AASLD, de nouvelles données sur la CBP confirmant l’efficacité et la tolérance à long terme d’IQIRVO® ainsi que de nouvelles analyses sur les mécanismes sous-jacents
07/11/2025
Les données intermédiaires de l’étude d’extension ouverte à long terme ELATIVE évaluant IQIRVO ® (élafibranor) démontrent une réponse biochimique soutenue, une stabilisation des marqueurs de fibrose et une amélioration [...]
Ipsen to present two late-breaking sessions at AASLD on new PBC data supporting IQIRVO®’s long-term efficacy, safety and mechanistic insights in fatigue
07/11/2025
Interim data from the IQIRVO ® (elafibranor) ELATIVE long-term open label extension trial demonstrate sustained biochemical response, stabilization of fibrosis markers and consistent trends in improvement of fatigue and [...]
Neurogastrx Announces NG101 Phase 2 Clinical Study Demonstrating Significant Reductions in Nausea and Vomiting Induced by GLP-1 Receptor Agonist Semaglutide
07/11/2025
Results, presented at ObesityWeek ® 2025, showed patients receiving NG101 saw 40% reduction in nausea incidence and 67% reduction in vomiting incidence Only 30% of patients who start GLP-1s for weight loss are still [...]
Nouscom Presents New Positive Phase 1/2b data of NOUS-209 at SITC 2025, Supporting Plans to Initiate Registration-Enabling Study for Cancer Interception in Lynch Syndrome Carriers
07/11/2025
Nouscom Presents New Positive Phase 1/2b data of NOUS-209 at SITC 2025, Supporting Plans to Initiate Registration-Enabling Study for Cancer Interception in Lynch Syndrome Carriers New data from Phase 1b/2 trial show [...]
Flare Therapeutics Presents Correlative Biomarker Analysis from the FX-909 Phase 1A Clinical Study at SITC 2025 40th Anniversary Annual Meeting
07/11/2025
− Demonstrates PPARG inhibition as a potential strategy to overcome immune resistance in advanced UC − Supports the planned Phase 1 cohort of FX-909 in combination with pembrolizumab; initiating in the first quarter of [...]
Werewolf Therapeutics Presents Data Expanding Its PREDATOR® Platform at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting
07/11/2025
Novel INDUCER™ T Cell Engager Platform designed to mitigate systemic toxicities Sequential dosing of INDUKINE™ molecules in preclinical model showed potent antitumor activity with improved safety First-in-kind real-time [...]
Elicio Therapeutics Reports Robust, Cytolytic mKRAS-Specific T Cell Responses Across Diverse Patient HLA in Ongoing Phase 2 AMPLIFY-7P Trial of ELI-002 7P and New ELI-004 Preclinical Data at SITC
07/11/2025
SITC abstracts highlight updated immunogenicity results from the Phase 2 AMPLIFY-7P trial of ELI-002 7P and preclinical data on the use of intratumoral ELI-004 (AMP-CpG) for solid tumor immunotherapy ELI-002 7P induced [...]
Nurix Therapeutics Presents New Translational Data from First-in-Human Clinical Trial of Oral CBL-B Inhibitor NX-1607 Demonstrating Immune Activation and Tumor Microenvironment Remodeling
07/11/2025
Data are being presented at the 2025 Society for Immunotherapy of Cancer (SITC) Annual Meeting SAN FRANCISCO, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical [...]
Precision Optics Announces Product Development Agreement to Deliver Next-Generation Augmented Reality Sub-Systems for Fighter Pilots
07/11/2025
GARDNER, Mass., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (NASDAQ: POCI), a leading designer and manufacturer of advanced optical instruments for the medical and defense/aerospace industries, [...]
BioAtla’s Mecbotamab Vedotin (Mec-V), an AXL-targeting ADC, Demonstrates a Median Overall Survival (OS) of 21.5 months in Subtypes of Refractory Soft Tissue Sarcomas
07/11/2025
— Mec-V demonstrates median OS of 21.5 months in patients with treatment-refractory leiomyosarcoma, liposarcoma, and undifferentiated pleomorphic sarcoma compared with approximately 12 months with approved agents — Mec- [...]
Trained Therapeutix Demonstrates RIDE-001 Trains Myeloid Cells for Anti-Tumor Immune Response in Preclinical Data Presented at the Society for Immunotherapy of Cancer (SITC) Annual Meeting
07/11/2025
-RIDE-001, a first-in-class nanomedicine, effectively trained myeloid progenitor cells to elicit myeloid-driven anticancer innate immune responses, as demonstrated in preclinical studies across multiple species DALLAS [...]
T-knife Therapeutics Presents Preclinical Data on PRAME-Targeted TK-6302 Highlighting its Potential as a Promising, Category-leading Therapy at the Society for Immunotherapy of Cancer (SITC) Annual Meeting
07/11/2025
-- Comprehensive TK-6302 data demonstrate preclinical efficacy and safety, supporting clinical readiness, alongside established scalable manufacturing --TK-6302 Clinical Trial Application planned in Q4 2025 for [...]
Coherus Oncology Presents at SITC Clinical Multiomic Biomarker Data for CHS-114, a Highly Selective anti-CCR8 Cytolytic Antibody
07/11/2025
– CHS-114 demonstrated robust and selective depletion of CCR8+ Tregs as well as favorable immune remodeling in tumor tissue from head and neck squamous cell carcinoma (HNSCC) patients – – CHS-114 administration resulted [...]
BioAge Labs to Present at Jefferies Global Healthcare Conference in London
07/11/2025
EMERYVILLE, Calif., Nov. 07, 2025 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ: BIOA) ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic diseases [...]
MiNK Therapeutics Reports Durable Responses and Immune Reactivation with Allo-iNKT Cell Therapy agenT-797 in PD-1–Refractory Solid Tumors at SITC 2025
07/11/2025
Durable survival and deep, lasting remissions in checkpoint-refractory, heavily pretreated cancers with median OS of ~23 months with agenT-797 plus anti-PD-1 Evidence of immune activation and tumor-immune remodeling [...]
IO Biotech Presents Pre-Clinical Data Highlighting the Potential of Additional Therapeutic Cancer Vaccine Candidates at the 2025 Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
07/11/2025
Pre-clinical data for IO Biotech’s next T-win vaccine candidate, IO112 targeting arginase 1, demonstrates anti-tumor activity with dynamic changes in the tumor microenvironment (TME) driven by the vaccine-targeted [...]
Tizona Therapeutics Presents Clinical Translational Evidence of Dual Innate and Adaptive Immune Activation with TTX-080, a First-in-Class HLA-G Antagonist, in Patients with Advanced Solid Tumors at SITC 2025
07/11/2025
Enrolling patients in ongoing randomized Phase 1b trial in MSS metastatic colorectal cancer, evaluating TTX-080 in combination with cetuximab + FOLFIRI SOUTH SAN FRANCISCO, Calif., Nov. 07, 2025 (GLOBE NEWSWIRE) -- [...]

Pages